Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Evolocumab vs LDL Apheresis Evaluated

Atherosclerosis; 2017 Oct; Kawashiri, et al

In patients with heterozygous familial hypercholesterolemia (HeFH) withdrawing from regular apheresis, treatment with evolocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) when compared with LDL apheresis, a recent study found. 11 patients with HeFH undergoing biweekly LDL apheresis were switched to a biweekly subcutaneous injection of 140 mg of evolocumab. The primary endpoints were percent changes in mean LDL-C and apolipoprotein B (apoB) serum levels. Researchers found:

  • Evolocumab significantly reduced LDL-C by 62.5% compared with LDL apheresis.
  • apoB and serum lipoprotein (a) levels were also significantly reduced.
  • No adverse effects were observed other than a mild reduction in vitamin E serum levels.
  • Biweekly evolocumab injection therapy is less expensive and less time-consuming compared to biweekly LDL apheresis.

Citation:

Kawashiri M, Nohara A, Higashikata T, et al. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis. 2017;265:225-230. doi:10.1016/j.atherosclerosis.2017.09.011.

This Week's Must Reads

Length of Stay & Early Discharge After Acute MI, Am J Cardiol; ePub 2017 Nov 22; Tran, et al

SBP Response and Discordant Trial Results, J Am Heart Assoc; ePub 2017 Nov 13; Huang, et al

Racial Differences in Natriuretic Peptide Levels, JAMA Cardiol; ePub 2017 Nov 22; Bajaj, et al

Gender Disparities in Cardiovascular Testing, J Am Heart Assoc; ePub 2017 Nov 29; Daugherty, et al

FDA Approves EKG Device for Apple Watch, AliveCor news release; 2017 Nov 30

Must Reads in Hypercholesterolemia

LDL-C Lowering with Evolocumab in Patients with PAD, Circulation; ePub 2017 Nov 13; Bonaca, et al

Does Evolocumab Lower Lipoprotein Particles?, Am J Cardiol; ePub 2017 Nov 8; Toth, et al

PCSK9 Inhibition & Neurocognitive Impairment, Circulation; ePub 2017 Nov 16; Mefford, et al

Eligibility for PCSK9 Inhibitors After ACS, J Am Heart Assoc; ePub 2017 Nov 9; Gencer, et al

CV Risk & Statins After MI in Young Adults, J Am Coll Cardiol; ePub 2017 Nov 14; Singh, et al